Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial
Premium

Premium: Valuing The Beast They Call Suzlon

The situation in Suzlon is a little complicated. We now know that Dilip Shanghvi of Sun Pharma fame bought a truckload of shares – with an 1800 cr. ...

Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial